Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × paricalcitol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 1 Resectable Pancreatic Carcinoma 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1 Adenocarcinoma of the Pancreas 1 Adenocarcinoma 1

Interventions

Gemcitabine 26 Fluorouracil 23 Oxaliplatin 19 Cisplatin 18 Leucovorin 15 Bevacizumab 14 Paclitaxel 12 130-nm albumin-bound paclitaxel 12 Capecitabine 11 Docetaxel 10 Albumin-Bound Paclitaxel 10 Irinotecan 9 Carboplatin 9 pembrolizumab 6 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Cyclophosphamide 6 Ramucirumab 5 Erlotinib Hydrochloride 5 Trastuzumab 4 Everolimus 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3 Ipilimumab 3 Gefitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03415854 2023-12-15

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡